It is worth emphasizing, however, that the assessment of the effectiveness of the use of TET inducers, DNA/histone methyltransferase inhibitors or histone deacetylase inhibitors in the treatment of AML with IDH mutations requires further research [86]. This evidence concerns the gene PRDM9 and acute myeloid leukemia.